3-cyclopentyl-1-tricyclo<3.3.1.1.^3,7>decanamine | 160013-53-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-cyclopentyl-1-tricyclo<3.3.1.1.^3,7>decanamine
• 英文别名: 3-Cyclopentyl-1-adamantaneamine；3-cyclopentyladamantan-1-amine
• CAS: 160013-53-6
• 化学式: C₁₅H₂₅N
• 分子量: 219.37
• InChiKey: RNAJJXSFVMIKGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-cyclopentyl-1-tricyclo<3.3.1.1.^3,7>decanamine 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 20.0h， 生成 3-cyclopentyl-N-methyl-1-tricyclo<3.3.1.1.^3,7>decanamine
  参考文献：
  名称：

  Fytas; Marakos; Kolocouris, Il Farmaco, 1994, vol. 49, # 10, p. 641 - 647

  摘要：

  DOI：
• 作为产物：
  描述：

  1-cyclopentyladamantane 在 盐酸 、 sodium azide 、 磺酰氯 、 硫酸 、 叔丁醇 作用下， 以 水 、 丙酮 为溶剂， 反应 15.58h， 生成 3-cyclopentyl-1-tricyclo<3.3.1.1.^3,7>decanamine
  参考文献：
  名称：

  Fytas; Marakos; Kolocouris, Il Farmaco, 1994, vol. 49, # 10, p. 641 - 647

  摘要：

  DOI：

文献信息

• Fytas George, Marakos Panayotis, Kolocouris Nicolas, Foscolos George B., +, Farmaco, 49 (1994) N 10, S 641-647
  作者：Fytas George, Marakos Panayotis, Kolocouris Nicolas, Foscolos George B., +

  DOI：——

  日期：——
• NEW SIGMA-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI- CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION
  申请人：Vamvakides, Alexandre

  公开号：EP2164479A2

  公开（公告）日：2010-03-24
• SIGMA( ) RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR MECHANISMS, EXHIBITING PROTOTYPICAL CYTOPROTECTIVE AND ALSO ANTICANCER ACTIVITY
  申请人：Vamvakides, Alexandre

  公开号：EP2400965A1

  公开（公告）日：2012-01-04
• SIGMA(s)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTION
  申请人：Vamvakides Alexandre

  公开号：US20100069484A1

  公开（公告）日：2010-03-18

  The present invention involves new and original sigma receptors ligands : (Mono- or di-alkylaminoalkyl)-γ-butyrolactones, their analogues aminotetrahydrofuranes, the (1-adamantyl)phenyl(s) alkylamines, the N,N Dialkyl α-[(adamantyl-1)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or -alkyl phenylamines, their enantiomers or diastereoisomers and their pharmaceutically acceptable salts, with pro-apoptotic and/or anti-apoptotic properties over cellular bio-chemical mechanisms, with anti-cancer, anti-metastatic, anti-(chronic) inflammatory, neuro-protective, anticonvulsive, antidepressive and nooanaleptic or sedative action.
• SIGMA RECEPTORS LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES, OVER CELLULAR MECHANISMS, EXHIBITING PROTOTYPICAL CYTOPROTECTIVE AND ALSO ANTI-CANCER ACTIVITY
  申请人：Anavex Life Sciences Corp.

  公开号：US20140228375A1

  公开（公告）日：2014-08-14

  The present invention involves new and original sigma receptors ligands: (Mono-or dialkylaminoalkyl)-γ-butyrolactones, their analogues aminotetrahydroturanes, the (1-adamantyl) benzene alkylamines, the N,N Dialkyl α-[(adamantyl-1)benzyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or diastereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Asteinizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, antimetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotective and cytoregenerative activity against the cytodegenerative diseases.